Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus

Chemotherapy

Volumn 54, Issue 4, 2008, Pages 315-322

  Bazarbashi, Shouki ^a   Abdelsalam, Mahmoud ^a   Amin, Tarek ^a   El Bassiouni, Mazen ^a   Soudy, Hussein ^a   Elweshi, Amr ^a   Alhusseiny, Hamed ^a   Rehman, Khaled ^a   Memon, Muhammed ^a   Ajarim, Dahish ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Esophageal cancer; Interferon ; Neoadjuvant chemotherapy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTICLE; ATAXIA; BLOOD TOXICITY; BRADYCARDIA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; PATIENT COMPLIANCE; PERITONITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; RECURRENCE; SURVIVAL RATE;

EID: 49149083564     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151353     Document Type: Article

References (28)

1. Geh JI, Crellin AM, Glynne-Jones R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-356.
2. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy G, O'Sullivan B, Sobin LH, Yarbro J: AJCC Cancer Staging Manual. Philadelphia, Lippincott-Raven, 1997.
3. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-284.
4. Rosenberg J, Lichter A, Liechman L: Cancer of the esophagus; in DeVita V, Helman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology, ed 3. Philadelphia, Lippincott, 1989.
5. Tanaka T, Fujita H, Sueyoshi S, Tanaka Y: Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal carcinoma: a preliminary report of initial experience. Chemotherapy 2007;53:449-454.
6. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
7. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168.
8. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR: Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003;21:4009-4015.
9. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, Kelsen DP: A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 1995;75:2197-2202.
10. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
11. Temeck BK, Liebmann JE, Theodossiou C, Steinberg SM, Cook JA, Metz DC, Shawker TH, Allegra CJ, Russo A, Pass HI: Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 1996;77:2432-2439.
12. Wadler S, Haynes H, Beitler JJ, Hu X, Fell S, Camacho M, Levine B, Wiernik PH: Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996;78:30-34.
13. Group MOW: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733.
14. Bazarbashi S, Rahal M, Raja MA, El Weshi A, Pai C, Ezzat A, Ajarim D, Memon M, Al Fadda M: A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. Chemotherapy 2002;48:211-216.
15. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W: Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
16. Kelsen D: Adjuvant therapy of upper gastrointestinal tract cancers. Semin Oncol 1991;18:543-559.
17. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
18. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-2174.
19. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
20. Kok T, Von Lanschot, J, Siersema PD: Neoadjuvant chemotherapy in operable esophageal cancer, a multicenter randomized controlled trial (abstract). Proc Am Soc Clin Oncol 1997;16:277.
21. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mantyla M, Modig H, Munck-Wikland E, Rosengren B, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1109; discussion 1110.
22. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-248.
23. Geh JI: The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002;38:300-313.
24. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
25. Malthaner R, Fenlon D: Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2003;CD001556.
26. Urschel JD, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
27. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-761.
28. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Australian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.